AM-101 in the Treatment of Acute Tinnitus (TACTT3)

The purpose of this research study is to test the safety and effectiveness of the study drug, AM-101

  1. Tinnitus Talk
    The purpose of this research study is to test the safety and effectiveness of the study drug, AM-101.
    AM-101 is tested for the treatment of tinnitus that started as the result of an injury to the inner ear or due to middle ear inflammation (otitis media). Subjects with tinnitus can take part in the study, if their tinnitus started within the last 3 months or within the last 4 to 6 months.

    TACTT3 (AT, BE, FR, DE, HU, PL, CH, UK, ES):
    Tinnitus onset no longer than 3 months (Stratum A) or between 3 months and 6 months (Stratum B) prior to randomization
    Estimated Enrollment: 600
    Study Start Date: January 2014
    Estimated Study Completion Date: February 2016
    Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
    Edu likes this.
If you have ringing ears then you've come to the right place. We are a friendly tinnitus support board, dedicated to helping you discuss and understand what tinnitus treatments may work for you.